ADAP - Earnings call transcript Q2 2020 | Adaptimmune Therapeutics plc

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Hello, and welcome to Adaptimmune Q2 Financial and Business Update. With me on today's call is Juli Miller. Juli, you may begin.

Juli Miller

Good morning and welcome to Adaptimmune's conference call to discuss our second quarter 2020 financial results. I would ask you to please review the full text of our forward-looking statements from this morning's press release. with during to and including a in latest projections differ results those making our due materially number filings anticipate this actual call could outlined We SEC. the of factors, portion will Chief our members with the and Officer, Adrian for of management Q&A. Rawcliffe, call, team Executive this our available me is for prepared be of other With Adrian Rawcliffe. that, I'll turn the call over to Ad?

Adrian Rawcliffe

and than the U.S. XXXX. for working now our to of track also with and with neck six that XXXX reported with response more a shortly initiated head half has you the ADP-AXMX and cancers. responses promising now the a patients promise remain France, be strong launch announced in with and with We've a different demonstrated trial, to II ASCO, on to and the Phase to you, gastroesophageal, thank everyone, sarcoma continued and lung and combining second types, of patient patients screened in in for quarter complete us. progress the Juli SPEARHEAD-X We with ADP-AXMX people productive, responses We trial durability new XX including a solid of cancer to Canada, neck we start of in in a new liver tumor complete very After cancers. pivotal would efficacy continued likely initiate the in we be therapy make Phase and head we as and required that cancer. to have Spain, year, synovial centers Thank we joining seen cancer. SPEAR trial, we At U.S. announced T-cell the total II in in in a ADP-AXMX U.K., pembrolizumab gastroesophageal bring

of to synovial granted potential regulatory meet Medicines support. medical for unmet need the the the validating sarcoma, PRIME recently us patients to this access with product significant further European addition, In Agency

to the finished market we've liquidity in with million funding sarcoma. the patients $XXX XXXX $XXX approximately million, into raised quarter on to and us our bringing of us total signals with we ADP-AXMX for Finally, focus enabling developing a and so trials seen and

For the from medical from of Dr. at at Spain, University data remainder our Clinic updates including cohort provide major by Liver conferences, to this presentation who we Bruno month. will clinical trial an oral dose XXXX, later Congress Navarra the of plan Sangro ADP-AXAFP the International in third present

in and to I plan data trial Phase our present additional durability sarcoma, from our also ADP-AXMX and QX. We trial updates SURPASS translational with synovial from patients

the We we trials in trial to -- delays still clinical evolving. recruited situation companies in we and sub-study will running COVID-XX U.K., our data be we everything sites already Canada. And across work discussed patients COVID-XX, of I cover. yet -- this biotech most the have experienced to want partially next pharma topic update from and impact Like radiation to as last of in have due as quarter meaningful, the and sufficient possible XXXX not recruitment and in Europe, allows. carry with but U.S. ground the and We have of have of our trials, impact on ready as those the we be to to locations, hit the the active is the centers each the done

have Anderson at impact Center an affected. region radiation of as that a MD we variations pandemic. seen so, of particularly sub-study between more in sites our phase is early for We instance clinical believe seen the Houston they and as Cancer Texas And in conducted to react with a we've regions trials, between the challenges

date. to the for based in results well, part trial on due continued has sarcoma benefit for progress in to synovial the pivotal However, enrollment in our opportunity seen patients clear SPEARHEAD-X to

busy very T-cell SPEAR at Our manufacturing Yard period. been facility Navy throughout has this the

share when period. We impact to as patients clearest able earlier or our patients the had whom a as whom for updates And continue reported to to we so. will this for some site-by-site our well we've on top as intervening in our we May, be any able evolves, country-by-country have trials treated whom particularly plan from others on the to safe patients was that the manufactured Later ADP-AXAFP year, and trials. trial United trial April on line whilst SURPASS has this cells data clearly, impact impact year, across basis in board we pandemic been States. an it this that believe in the data continues new in it's have we and to for patient treat do But and

to indications guides progress next-generation starting trial Looking combination phase beyond data a II new promise cancer continue and we gastroesophageal with us. into trials, test and in enhancements the later with will XXXX, as therapies Phase

future with will We our to develop completed program our as people future also off-the-shelf clinical therapies of partnership cancer. to planned will such we trials. increasing this manufacturing for needs continue earlier also year preparing Astellas our we ongoing by cell meet the and with and for as capacity the part pursue vision opportunities, for the to We're continue of allogeneic deal the

commercial including our In development is commercial addition, our manufacturing towards preparation scale. of up, ramping capabilities

pipeline. to in best We SURPASS important, using the therapies named recently the to which in to on cell enables I'm our process, and global of therapy. Journal. to research our manufacturing worked GMP This the we maintain partners our pleased Philadelphia work need includes my we be where to have be to year. with its facility Philadelphia personal in dedicated to start associated patients production, own of are and challenges that our remain the a vector that Adaptimmune we Throughout tirelessly the in this convinced pandemic, a for more colleagues be leader to ability dedication have on who us our I period, later in While midst the of external innovate intend this by carry one to manufactured crucial places are of by humbled trial efficient. vector continued receive Business

delivering of a place lives by cancer cell people with designing want Adaptimmune and Our transforming who to people work. to makes shared the like where passionate therapies, cancer cure mission,

ongoing lives, make discussion inequity, as racial the are black everyone themselves and about to should all. whether about we challenge to However, relates particularly it welcoming nurturing equally

to And I'll As ensure open Operator? everything to and I great share a we And this is do the my a CEO, that future. a supported where call up commitment in can I'm committed all colleagues now, this course. colleagues place can feel place bright to questions. know be, Adaptimmune to see

Operator

question from the of Marc Our first Thank Cowen and Frahm line with Instructions] comes you. [Operator Company.

is line ahead. Please open. Your go

Marc Frahm

for believe, additional presenting new taking you patients? and your Thanks both in is data my Or presentation patients, be Is we'll I the the prepared AFP that in year programs. mentioned EASL later AFP that question. SURPASS alongside presentation of the going in new for line to going patients? AFP happen Adrian, remarks, see to top that

Adrian Rawcliffe

going Norry at the the to and I'm ask Elliot? the in with at coming end outline Elliot ILC what's year So, AFP. to August further of on

Elliot Norry

Ad. Thanks,

what in clear be just to EASL. expectations So, for will presented be about

least on what presenting Conference include don't First the EASL. group for those cancer And entire we any you gave patients in update May hasn't And trial, safety for further non-HCC, in EASL at specific top well update the we have is for patients patients. the be of an information ASCO. time. considerably year. an presentation three, will around we the line non-hepatocellular which can results there -- of at beyond would the not of And that been end beyond expect as of that, And rest to much will AFP the as on clinical all, plans update mostly I expect more not the cohort, beyond

Marc Frahm

people Can Today, to of year have Okay. you and How of impact screening you kind can where speak now you Great. just has if of in generally, highlighted maybe -- pulls it? Adrian access both than, just patient COVID. to were adapted added much some trials on more? your from speak And less pushes then areas then of impact the are kind active to maybe, also or you the a enrollment are just seeing lessened, COVID say, responses, of enthusiasm the today and but obviously, more you kind or ago? that Elliot,

Elliot Norry

a to in their concern our really at that's look We really ago, and saw were didn't manage marked a the data and can And really April. and that's tell whatnot. screening to just been screening if March, started, and exposure I not concerned back when go compared to about -- this that year March April, So, they think in beds and have from across that to have I'm patients, cutback traffic really capacity helpful. you answer the centers -- minimizing in ICU ago. since to just I I'd trajectory what's that the year largely staff programs centers a a

So, improved do things does think And I it that really then. region-by-region. since depend have

worse regions and on that really. heading, have across over day-to-day really virus regions say a are have handle the we so screening we don't our programs. change until seeing I gotten is that recently Some think story the I is again, where could will

to and without needs to our have to what be and It's the really our have safe month protect flow hard their screening to of around exception and with when will of their a would where centers we employees also perhaps specific large. manage ago I met can walking than by a different be and respect SPEARHEAD-X we the now. better for to month patients that to from trials think, sort our And both been of in treatment globe, screening patient true advance their more not the projections with if and when from it ability treat the has and was patients worked COVID-XX, manufacturing possible. best --

Marc Frahm

Great. Okay. you. Thank

Adrian Rawcliffe

Marc. Thanks,

Operator

Tony Thank question Capital. of ROTH you. Butler the line And with comes our next from

Your Please line is go open. ahead.

Tony Butler

pembro refractory them. the which for to be, therapy? would screen see what be do patients about sequencing of which that pembro when fact, may cell be pembro on itself. be cell that you about Two how sequencing I cancer, indication after? therapy. the patient may. have neck think it understand is be actually -- possible you're is if population questions, how and trial an when would before you're and able you -- morning. One you interesting experiment pembro them, to you see It in question Thank understand and that you this pembrolizumab. head that add Importantly, will very head much. neck in a I'm second will to And in end then, in is I'd therapy very relative again, relative does screening you to think the cell the up a to where or those to like dosing And you cancer Good the trying given actually

Adrian Rawcliffe

Thanks, Tony.

to I I think be trial, think Elliot the of of I those think protocol -- will several And there's else that for back because that maybe the I'll well because ask can approach walk then Elliot? questions. we'll if with. can answer loop that we help trial through -- something as that

Elliot Norry

Hi. Yeah. again. Thanks

pembrolizumab Trial we though, design, details and there presented, poster on who generally you or when that time presented pembrolizumab. the -- don't recently know, that So are patients time. started at length In be with as to may about won't greater have cells it either respond be that will be question your will trial, would the just sequence, be general, and at with in on -- a when idea ready that combination data pembrolizumab ESMO at in in will their that provided patient have trial patients Progress screening treatment answer or that there to we're be for naive progress pembrolizumab,

on line who pembrolizumab stay patients would for to indicated first respond and treatment. it -- pembrolizumab, initially is So as of

soon as we receive a after not following pembrolizumab really and documenting to possible line -- clinical had see a that pembro as line continue as from as So, this benefit first pembrolizumab sequence patients alone. have first cells

Tony Butler

fair to but after had pembro But continue get Thanks. in perfect. they they they've pembro on and virtually -- say? so -- cells. basically, That's all cases as will cells we That's get

Elliot Norry

Yes.

Tony Butler

Thanks, Adrian. Elliot. Thanks,

Adrian Rawcliffe

Thanks, Tony.

Tony Butler

Thank you.

Operator

question comes Bansal line next Citigroup. our Mohit with And from you. Thank of the

Please open. is ahead. go line Your

Mohit Bansal

Great. question Thanks very good my for morning. taking and

patients therapy why late at So, to therapy? they and wanted between versus the just not cell from whether where time in is to understand just asking the context are therapy, in are is time question. mean, non-responding -- pembro understanding too I difference of administer Can like is initiation either what after that? you I'm -- as cell there us have versus progressing the a the to what -- patient on follow-up when Tony's -- responding cell you so it administering progressed? progressing to is of help please point

Adrian Rawcliffe

Elliot?

Elliot Norry

generally who as unmet cell detail with it's poster. have not continued explanation significant of that potential patients patient possible the pembrolizumab medical investigator that have question, to of had I'm But point defer rapidly ESMO and therapy But at need patient study not an if benefit beyond be until have trying has position wait really the having where in would do ready and be your respond as sort then that to to go as for sequence proceed. a the discretion to we're so combination of of the progressed it point to going pembrolizumab. greater from to continued therapy, not and answer

Mohit Bansal

on cancer. then, another question And liver Got it.

then responses, some have internal in with patients Phase SPEARHEAD-X other bar Did noting? you many see, And with would biomarkers So did actually have done respond, far, kind and two trials? have like patients if these move II you the worth I response, not trial correctly. is, see it if the two think seen follow-up other one we these which just you ahead any do be you understand complete would that I you the of

Elliot Norry

Yeah.

than additional defer Congress. response weeks a a to any away is for presentation. I those and and parameter, only respect of the response. Liver Dr. Phase duration on There details the to for that's there we whatnot, International patients, but to going of presentation allow combination complex it's look just and his some of proceeding respect with further really single think biomarkers are So, to more rate make would at the -- and Sangro should embargoes just study, II With to we bar I'm couple to

Mohit Bansal

Got it.

Adrian Rawcliffe

of Previously, benchmark. the of a patients starting Mohit, the we're we've XX of being of good three most thumb -- signal out sort used whether of a seeing rule

characterize in two us two Now responses were program is SURPASS nature generally speaking, therapy, obviously, seems to more late-stage the tractable out a to and of ongoing dose we sufficient cell cancers. recruitment we and study the cohort in understand gastroesophageal in at responses. the further saw in persuade signal that the there to out think development of XX hence, patients a response AFP there and the lowest of of that reasonable the three rate But

Mohit Bansal

you, you, Adrian. Elliot. This very is Thank Great. helpful. Thank

Operator

the Guggenheim next Thank you. And of line with our question from comes Michael Securities. Schmidt

open. line ahead. go Please Your is

Kelsey Goodwin

numerous Thanks Hey, more noticing types this you taking for that are Michael. tumors. likely you. cohort is Kelsey responses guess, I to question. that in and on now our you any AFP seeing guess I to tumors, for what expect cohort the Thank I of or who we're solid TCR therapy are patterns see? respond? are tumors or And specifically guess, do kind what non-HCC across of to you for then which in tumors seeing tumors the

Elliot Norry

think separate I two So, -- that answers. it I'll into

program. to with of SURPASS First respect MAGE-AX all, the

we of that be forward activity in where study we those SURPASS forward ones going previously anti-tumor that we've focusing types. degree are the tumor date expect seen tumors stated to that the and think a the might on we'll responses to I see going

we those So bladder four focus may explore to that's look the tumors that head gastroesophageal. and any That's the and that, will specifically, and how lung that other on we've and approach to investigators. we of study centers ability say and from not but to standpoint neck, continue in exhausted tumors study

by the in with I of the think expression, it's to AFP tumors. but may and those the in the And it's of tumor MAGE-AX non-HCC of respect tumors also They degree that of really date. has to study, a that in then clinical to experience with variety cohort we are some of frequency guided see. our different do types tumors, expression rare

types, you germ look there of tumors, rare frequency expression some express at the gastric AFP, rare AFP tumor cholangiocarcinoma, cancers If other that are a cell in hepatoblastoma.

with treatment would tumor had and study their that numbers study. own. And never individual received investigators types on some I that So, the there these cohorts options rare try we find the patients from are limited requests really include in in to think we to

So, a basket essentially them are that we tumors. that non-HCC opened is a of cohort

Kelsey Goodwin

much. Got it. so Thank you

Elliot Norry

Sure.

Operator

Jim Thank from Wells of the you. line And Fargo our comes Birchenough question next Securities. with

ahead. Your go line Please open. is

Nick Abbott

Nick Jim Hi. for It's morning. Good morning. on this

announced on in opening trial. cohort. First you would prior an dose levels the be three question million is SURPASS X May, that that cells believe at thee two I to and patients expansion launched, and will be treated

on investors those and Thank for have provide the can follow-up. I then you. an update opening expectations data expansion what patients the you have a that And presentation? timing cohort? three should So, And of

Elliot Norry

the So, about later specific We we're do to SURPASS et in cohorts, this the on not plan time. provide updates update an cetera. patients at patients, providing year

Nick Abbott

T-cells Okay. Thank competent obviously, is you. product for the that And CDX T-cell that designed such then, receptor. become

had So, CDX to and T-cells the have that remain ensure competent the patient? look you given them samples they opportunity to you've patient after from at the

Elliot Norry

answer, -- disappointing. I sort be of it's But year. to the the that that in same going about to later update it's an information provide at we're hate So,

Nick Abbott

has I there try programs, on one you that well. an announcement is in Astellas, a same earlier been which with you I'll had that the provide suspect was Okay. believe updates pluripotent and formal you is the program? answer very the induced more, said T-cell on selected. I collaboration as -- where And Can a year candidate any

Helen Tayton-Martin

to This Helen Hi. Happy Tayton-Martin. take that. Yeah. is

successfully our we first at Astellas will of which program we the be -- our nominated think, moving with I May is end TCR, a have update an forward target, And to HiT, the first jointly also mentioned that in program. HLA-independent date.

an forward this at time see joint that and program, not a bit disclosing but the we're cell surface continuing to on track it antibody. can point. like that on of is But move TCR So a target a protein,

So, collaboration forward. how we're moving really with pleased is the

Nick Abbott

the Thanks, And what that Helen. the roughly is moving of timeline clinic? into

Helen Tayton-Martin

that's point I And be at first be program -- program would same but something are So time. also in further technology, using the disclosing to into that not we that our the happens clinic the advanced. that MAGE-AX this but say will

So, these some not cetera, imminent. things on -- et forward. but not when it's we're of are it tracking the exactly regulatory on processes, extent, depends CMC To disclosing some feedback

Nick Abbott

Thanks all. Thanks, Okay. the for updates.

Helen Tayton-Martin

you. Thank

Operator

Thank question line from comes Leerink. with Jonathan you. the next Chang And our of SVB

open. is Please line Your go ahead.

Jonathan Chang

and questions congrats taking for Thanks morning. my on progress. the Good

the have at ASCO the confirmed point? unconfirmed the question, been time First this at responses reported MAGE-AX second-gen program of with

Adrian Rawcliffe

issued we So, information the this haven't on we year. new later any on do that. And will clinics

Jonathan Chang

Got it. to And second question, that. related guess, I

both the the are about second-gen how are about For first-gen of programs, and MAGE-AX should thinking responses? reasons in thinking sarcoma, the durability beyond we for durability? for confidence how you of What durability benchmarks responses? And be

Adrian Rawcliffe

question. good A

process I because of to gathering patients, and in we're are for think time little a the difficult, me, requires reasons those. the confidence confidence and data data and

lot which study, all as fact The we nature escalation. need So, the want that study. the get at clear, we understand are -- the more first on an responses stats, and the fantastic. we early-stage dose patients to and a longevity responses I we rate saw for through and of But is study SURPASS to more go these in example, the it's about is doses the them be of

So, those I understand patients. that. -- as of in think we'll we terms And recruit

I and depends indication we're setting that In on going benchmarks largely after. question think I think terms the the of what the are, of that

settings information this go bit a I nature gastroesophageal year data, as the on trial the more bit on where out in it's at -- up a we're of about that what that to and third got see later those that an of to is where there into second and have think elsewhere, share settings. And we've we we'll are benchmarks line we talk what next think, time we year. when more setting I the else are understanding going depend signal. But the the

Jonathan Chang

program, data regards to question, from And are promising with generation with just program? it. the -- pipeline you prioritization next-gen Got Thank the how MAGE-AX last the thinking potential early about first zooming you.

Adrian Rawcliffe

first is -- a strategically that mean, there's good I unmet signal a have robust the that think that signal we And need, such really for a definitely see and commitment I That's medical program. we a with will very there the clear as us, we've generation in is the where signal question. done, sarcoma. made

we're to it's back We generation as are first the of into think data the to as translational evolution a feed quite and one, with these that And do research we -- that into market. back manufacturing. moving products, program can that, real-time because getting I forward can there's important can be fast because we rapid,

pilot the where be benefit pipe. we things that the -- now sub-study. the -- I always those potential for as cell to objective Having And better benefit I possible. the so, will to ADP-AXMX product. that, Rather, has coming for And think with finished patients something is anybody the has to constantly exception quickly don't the there said trial of significant as trial our don't be benefits think down a perfect radiation see therapy move -- benefit enrolling waiting

And focus MAGE-AX, much the SURPASS in very on combination gen pembrolizumab the that's the one on progressing product program towards sarcoma, with so, so -- for obviously have second head the for and we beyond in the cancer the with approaches the neck gen where study, head of is -- registration. outside the one radiation augmented generation example, of on sub-study, our and

to space this our that understand -- sort point that's our that about our our companies And quickly general that that's stage then and if we are of comfortable existing research execute us are emerging -- a space. of market. got across get fact for raise therapy also I want feature the pipeline. of think successful, So in will I on generally -- products the integrated prioritize capabilities they here as And and how early the enable the But -- it we conceptually cell -- the just to with are think of cannibalize we have to to

Jonathan Chang

taking the questions. Got it. Thanks Thank you. for

Adrian Rawcliffe

Jonathan. Thanks,

Operator

of question Mizuho has line next Fung with come from Our Instructions] Securities. [Operator the Gabriel you. Thank

open. is go Your ahead. Please line

Gabriel Fung

Hi, of is Goldstein. Mara on Gabriel everyone. This behalf

on here Just question … data have a the

Adrian Rawcliffe

Hi, Gabriel.

Gabriel Fung

Hi.

SURPASS. which taking target sales at And in manufacturing, for the SPEARHEAD? we For are using any expect Could guiding there Navy you expected provinces? to Thanks facility Yard that on the the on Are yield ESMO? question. manufacture be to and also cost differences for

Adrian Rawcliffe

Sure.

if in headlines So, press look carefully of ESMO the release, for I'll very And to the SURPASS. our you'll that take you first and one we're see September. guiding that in on QX

So, going I'll the answer Yard secondly, And be the hand that at to not to costs it's is no, to to John then over -- Navy that. manufacturing ESMO. and talk of about the

John Lunger

Yeah.

So, in this of is John. -- terms

things of terms manufacturing is to use in-house In the we we in cost, we later the earlier year. of plan our that on one that have which mentioned vector, the own

will optimize vector in-sourcing run is also how Yard facility. just positive One continuing COGS. do certainly, a we Navy impact thing other we're on So, to actually have the

that So, and of bit one time overhead optimize resources into to in a example, goes the and we're investing the those. fair reduce each of process for allow electronic us systems, which

we So, our that and continuous making I'd big of terms some along. and say improving we're changes of as it's optimization in cost step efficiency a go process fairly

Gabriel Fung

not Great. here. -- outpatient or one then, the or this future? whether the about in the -- wondering, could company the be was use And how does your a in quick potential company candidates just exploring actually, actually Thanks. follow-up setting your assets ever I has really Thanks. think just

Adrian Rawcliffe

Helen, do that? to you want to talk

Helen Tayton-Martin

great a question. That's This is Helen. Yes.

answer the yes. is think I

we that, in as forward. what quite as that. to as exactly about look Clearly, roll say exploring a depends setting, like thinking soon that are will to but on anything. treat too We're community the it's much a safety bit We ability

with tracking therapy. So, our been that I we're think -- has pleased and how with quite

definitive at how But look. answer exploring point, are we yes, that will have to So, our this as it. don't

Gabriel Fung

Thank you everybody.

Adrian Rawcliffe

Thanks.

Operator

you. of And with question ROTH Thank another Capital. from the line do we have Tony Butler

ahead. open. Your line Please is go

Tony Butler

there's brief. therapy. Yes. Redosing an really The is Helen's much and dosing then in with really -- The is be now, ask you comment multiple about enlightening another. outpatient. therapy of question single does want and do cures curious scheme such the across really, to of that interesting, multi-dose the we to as outpatient research are all a when is think fast about to just setting Adaptimmune But view forward, cures, things respect cannibalizing a letting share at generate truly question made me Right for a unlikely lot grand you dose around single companies last Thanks a just as cell think to comment share clearly, the I'm in effect you dose. exploration. that it's most most existing Thank solid options. products, optionality community of when we have you. on variety -- Elliot, going you very come least I'll have tumors? or

Adrian Rawcliffe

Yeah.

So, take it. maybe I'll

and isn't I to answer to redosing looking curative experience we in Tony, have broadly are know, patients We patients we single approaches what and/or patients in at therapies. the some mind, don't we there get -- between suggest are in continued in get is response. patients is I who think And redosing do order the definitely mixed. our dosing second trials. are of short multi-antigen the to order that target to antigen. or of And -- There others a to there dynamic versus in expression only we're there bearing the cells where that infusion would curative therapies of have and any is facet some is we responded somewhat where have other

dosing on think So, the I multiple will jury whether second required. is be out

extra on context lymphodepletion, dosing. obviously I third or of the think paradigm hurdle in an that the second current puts of

easier, think then lead well. would evolution as particular, in a curative obvious lymphodepletion responses possible. a the able to other there's we to course potentially that Allogeneic to help is get that dosing and our prolonged it's address about that lastly, interesting extent the different place regimen, drivers to around product platform, as So, might routine in be well therapy And where formats multiple make due more to being of that potentially even as potentially some dosing the durable and more

therapies. explore how we as -- to and will treat patients cell those best we think all elements, of the continue our So about to with

Tony Butler

Adrian. you, Thank

Operator

And any showing And over to no I'm you. conference further I questions this Rawcliffe would turn remarks. Adrian back Thank the time. like to at for further

Adrian Rawcliffe

range broad progress T-cells Thanks of Thank We've that, across everybody made the I first you much. we you generating sarcoma make and And look very half the updating with to XXXX. And a with all to solid to great bring cancer. forward as call. and SPEAR progress today. are in pushed your time people aggressively, continue Thank questions of we for we'll to with our your responses the We've close products in forward you. tumors.

Operator

thank conference. Ladies for Everyone great have disconnect. This the and in day. does participating you a you conclude and all gentlemen, today's may program

Adaptimmune Therapeutics (ADAP) 9 Aug 202020 Q2 Earnings call transcript